• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增生异常综合征感染的流行病学及危险因素

Epidemiology and risk factors for infections in myelodysplastic syndromes.

作者信息

Sullivan L R, Sekeres M A, Shrestha N K, Maciejewski J P, Tiu R V, Butler R, Mossad S B

机构信息

Department of Infectious Disease, Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.

出版信息

Transpl Infect Dis. 2013 Dec;15(6):652-7. doi: 10.1111/tid.12130. Epub 2013 Sep 9.

DOI:10.1111/tid.12130
PMID:24010918
Abstract

We conducted a case-control study to describe the epidemiology and risk factors for infections requiring hospitalization in patients with myelodysplastic syndromes (MDS). Of 497 patients identified, 103 patients developed 201 episodes of infection. The probability of acquiring an infection 1 year from date of MDS diagnosis was 15% (95% confidence interval [CI] 12-18%). Patients developing infections had decreased survival compared to those who did not (P = 0.007). Significant risk factors for infection were higher risk MDS (hazard ratio [HR] = 2.7, 95% CI = 1.7-4.1, P < 0.0001), nadir absolute neutrophil count <500/mL (HR = 1.8, 95% CI = 1.2-2.7, P < 0.007), chronic obstructive pulmonary disease (HR = 2.6, 95% CI = 1.4-4.9, P < 0.003), history of other malignancy (HR 2.0, 95% CI = 1.3-3.1, P < 0.003), and autoimmune disease (HR 2.9, 95% CI = 1.4-6.0, P < 0.005). Age, nadir platelet count <20,000/mL, diabetes mellitus, and MDS treatment were not significant risk factors. Pneumonia was the most common infection, and bacteria the predominant pathogens.

摘要

我们开展了一项病例对照研究,以描述骨髓增生异常综合征(MDS)患者中需要住院治疗的感染的流行病学及危险因素。在确定的497例患者中,103例患者发生了201次感染。自MDS诊断之日起1年发生感染的概率为15%(95%置信区间[CI] 12 - 18%)。发生感染的患者与未发生感染的患者相比,生存率较低(P = 0.007)。感染的显著危险因素包括较高风险的MDS(风险比[HR] = 2.7,95% CI = 1.7 - 4.1,P < 0.0001)、最低绝对中性粒细胞计数<500/mL(HR = 1.8,95% CI = 1.2 - 2.7,P < 0.007)、慢性阻塞性肺疾病(HR = 2.6,95% CI = 1.4 - 4.9,P < 0.003)、其他恶性肿瘤病史(HR 2.0,95% CI = 1.3 - 3.1,P < 0.003)和自身免疫性疾病(HR 2.9,95% CI = 1.4 - 6.0,P < 0.005)。年龄、最低血小板计数<20,000/mL、糖尿病和MDS治疗不是显著的危险因素。肺炎是最常见的感染,细菌是主要病原体。

相似文献

1
Epidemiology and risk factors for infections in myelodysplastic syndromes.骨髓增生异常综合征感染的流行病学及危险因素
Transpl Infect Dis. 2013 Dec;15(6):652-7. doi: 10.1111/tid.12130. Epub 2013 Sep 9.
2
Infection in the myelodysplastic syndromes.骨髓增生异常综合征中的感染
Am J Med. 1991 Mar;90(3):338-44.
3
Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database.综合医疗实践研究数据库中自身免疫性疾病患者发生骨髓增生异常综合征的相对风险
Cancer Epidemiol. 2014 Oct;38(5):544-9. doi: 10.1016/j.canep.2014.08.003. Epub 2014 Sep 2.
4
Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.定义急性髓细胞白血病和骨髓增生异常综合征患者造血细胞移植后与中央导管相关的血流感染的发病率、危险因素和对生存的影响。
Biol Blood Marrow Transplant. 2013 May;19(5):720-4. doi: 10.1016/j.bbmt.2013.01.022. Epub 2013 Feb 1.
5
Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.诊断时合并症的评估可预测骨髓增生异常综合征患者的预后。
Leuk Res. 2011 Feb;35(2):159-62. doi: 10.1016/j.leukres.2010.06.005. Epub 2010 Jul 1.
6
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.乳腺癌辅助化疗期间使用粒细胞集落刺激因子后发生急性髓系白血病或骨髓增生异常综合征。
J Natl Cancer Inst. 2007 Feb 7;99(3):196-205. doi: 10.1093/jnci/djk028.
7
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.预测接受阿扎胞苷治疗的骨髓增生异常综合征/急性髓系白血病高危患者的感染:一项回顾性多中心研究。
Am J Hematol. 2013 Feb;88(2):130-4. doi: 10.1002/ajh.23368.
8
Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population.根据世界卫生组织分类的中国人群骨髓增生异常综合征危险因素的病例对照研究。
Am J Hematol. 2011 Feb;86(2):163-9. doi: 10.1002/ajh.21941.
9
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.在荷兰阿扎胞苷同情用药计划中,第一个阿扎胞苷周期后血小板倍增是骨髓增生异常综合征(MDS)、慢性粒单核细胞白血病(CMML)和急性髓系白血病(AML)患者反应的有希望的预测指标。
Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.
10
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.马利兰剂量强度与骨髓增生异常综合征或急性髓系白血病患者行减低强度异基因外周血造血干细胞移植的结局。
Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2.

引用本文的文献

1
The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus.伴发糖尿病的骨髓增生异常综合征的临床特征、基因突变和转归。
J Cancer Res Clin Oncol. 2024 Feb 2;150(2):71. doi: 10.1007/s00432-023-05591-4.
2
Increased prescription rate of anti-infective agents after diagnosis of myelodysplastic syndromes.骨髓增生异常综合征诊断后抗感染药物处方率增加。
EJHaem. 2022 Mar 25;3(3):775-784. doi: 10.1002/jha2.422. eCollection 2022 Aug.
3
Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web-based case vignette questionnaire: The MINDSET study.
荷兰骨髓增生异常综合征患者感染预防管理的网络病例 vignette 问卷调查:MINDSET 研究。
Eur J Haematol. 2022 Oct;109(4):381-387. doi: 10.1111/ejh.13820. Epub 2022 Jul 6.
4
Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy.骨髓增生异常综合征中的感染与分期及治疗的关系
Mediterr J Hematol Infect Dis. 2018 Jul 1;10(1):e2018039. doi: 10.4084/MJHID.2018.039. eCollection 2018.
5
Monocyte function in patients with myelodysplastic syndrome.骨髓增生异常综合征患者的单核细胞功能。
J Leukoc Biol. 2018 Sep;104(3):641-647. doi: 10.1002/JLB.5AB1017-419RR. Epub 2018 Apr 14.
6
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.骨髓增生异常综合征患者心血管死亡的风险及时间
Blood Adv. 2017 Oct 18;1(23):2032-2040. doi: 10.1182/bloodadvances.2017010165. eCollection 2017 Oct 24.